Get in Touch

FOR PHARMA & LIFE SCIENCES EXECUTIVES

If you are within five years of a transition, the board seats are going to someone else — and this page explains exactly why.Board recruiters Google you before they call. What do they find?For most senior pharma executives — VPs of Clinical Operations, Regulatory Directors, SVPs of Medical Affairs, Heads of Commercial — the answer is almost nothing. A LinkedIn profile. A company bio. A press release from 2019 you didn't write.That is not a reflection of your expertise. It is a reflection of how careers in this industry are built. And it is fixable.

THIS IS FOR YOU IF— You are a pharma or life sciences executive — VP, SVP, C-suite, or Director-level with 20+ years — planning a transition in the next one to five years— You have been passed over for a promotion, an advisory role, or a board consideration that should have been yours— You are currently employed but know the industry well enough to see what is coming — and you want the pipeline built before you need it— You have tried networking, conferences, and keeping your LinkedIn current — and the right opportunities are not materializing the way they shouldIf none of these fit, this page is not for you. If one of them does, keep reading.

The problem nobody in your position talks about out loudThe executives landing scientific advisory board seats at early-stage biotechs, speaking at DIA and BIO, getting calls from executive search firms — they are not more experienced than you.In most cases they are not even more accomplished.What they have that you do not is a published body of work. Articles in the publications your peers actually read — Pharmaceutical Technology, Applied Clinical Trials, RAPS Regulatory Focus, BioPharm International, Directors & Boards.Published expertise compounds. Each article builds on the last. Over 9 to 12 months, a body of work establishes you as a known quantity — the kind of person a biotech founder points to and says, "I've been reading her for a year. She's exactly who we need."Without it, you are invisible to the people doing the pointing.

I have spent 25 years solving exactly this problemMy name is Judy Curtis. I am a senior communications strategist and ghostwriter specializing in life sciences and technology executives.Before building SIPR Encore, I spent two and a half decades crafting brand narratives for technology and life sciences organizations — learning how to take genuinely complex ideas and distill them into messaging that resonates with exactly the right audience.What I noticed, repeatedly, was that the most impressive people in the room were almost never the most visible ones. Not because they had nothing to say. Because they had never had a system for saying it.SIPR Encore is that system.

Here is exactly how it worksWe meet in regular structured sessions — efficient, designed around your schedule.I interview you. I ask the questions that surface the frameworks, the judgment calls, the hard-won perspectives you have accumulated across your career. The things you could talk about for hours.Then I do the writing, the editing, and the placement.You never sit in front of a blank page. You have a conversation about what you actually know. I handle everything else — including placing the work in the publications where your target audience is already reading: biotech trade journals, pharmaceutical industry platforms, LinkedIn Articles, and the governance and science publications that board recruiters and conference organizers actively monitor.You talk. I write. The market finds you.

What this has produced for clients

VP OF PHARMACEUTICAL DEVELOPMENT — AGE 56Zero external visibility. Three years from retirement. Started building her body of work with us. Within 14 months: a scientific advisory board invitation from an early-stage biotech, equity compensation included. Active conversations with two executive search firms who reached out after finding her published work."I thought I was too late to build a reputation outside my company. Turns out I just needed help translating what I know."---DIRECTOR OF REGULATORY AFFAIRSWanted to leave corporate but had no consulting platform and no external brand. Published regulatory insights for 12 months while still employed. Left at month 15 with three committed clients already signed. Now fully independent, working selectively.---VP OF CLINICAL OPERATIONS — PASSED OVER FOR SVP TWICEStrong performance reviews. No external visibility. Published on clinical trial strategy for nine months. Promoted to SVP at month 13. Her CEO cited her "emerging industry leadership" — the same leadership that had existed for years and simply had not been visible.

THE GUARANTEEStart with a single session. No commitment beyond that.We define your publishing territory, identify the publications where your target audience is active, and develop your first three article ideas.If you leave that session without a clear path and real momentum, you do not continue. That is the whole risk.Most clients describe the first session as the clearest they have felt about their professional direction in years.

The encore chapter is available to you. Most executives never claim it.Board seats. Advisory roles. Consulting work that uses everything you have built. A professional identity that does not depend on any single employer.That chapter goes to people who made their expertise visible — methodically, before they needed to. The executives who built it started 12 to 18 months before they needed it to pay off.If you are within five years of a transition, the right time is now — not after the next reorg.

Email [email protected]

Two sentences about your background and what you want to build.
I respond within 48 hours.